MGX (Metagenomi Therapeutics) ROE % Adjusted to Book Value: -168.22% (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.19
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics ROE % Adjusted to Book Value?

Metagenomi Therapeutics MGX -0.83% 10 ROE % Adjusted to Book Value is -168.22% as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Metagenomi Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -62.24%. Metagenomi Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 0.37. Metagenomi Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -168.22%.

Metagenomi Therapeutics ROE % Adjusted to Book Value Related Terms

Metagenomi Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics ROE % Adjusted to Book Value Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -271.14 -117.55

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -186.50 -139.25 -87.18 -140.71 -168.22

MGX vs KALA, HYPD, APLM: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's ROE % Adjusted to Book Value falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics ROE % Adjusted to Book Value Calculation

Metagenomi Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-44.67% / 0.38
=-117.55%

Metagenomi Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.24% / 0.37
=-168.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -168.22% mean?
Metagenomi Therapeutics (MGX) has a ROE % Adjusted to Book Value of -168.22% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' ROE % Adjusted to Book Value too high?
Metagenomi Therapeutics' current ROE % Adjusted to Book Value is -168.22%. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' ROE % Adjusted to Book Value compare to KALA and HYPD?
Metagenomi Therapeutics' ROE % Adjusted to Book Value of -168.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current ROE % Adjusted to Book Value is -168.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current ROE % Adjusted to Book Value of -168.22%. The current ROE % Adjusted to Book Value is -168.22%. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current ROE % Adjusted to Book Value is -168.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price